Inhibition of phosphodiesterase 2 by Bay 60-7550 decreases ethanol intake and preference in mice
- 59 Downloads
Alcohol use disorder (AUD) is a chronically relapsing condition, which affects nearly 11% of population worldwide. Currently, there are only three FDA-approved medications for treatment of AUD, and normally, satisfactory effects are hard to be achieved. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling has been implicated in regulation of ethanol intake. Phosphodiesterase 2 (PDE), a dual substrate PDE that hydrolyzes both cAMP and cGMP, may play a crucial role in regulating ethanol consumption.
The present study determined whether PDE2 was involved in the regulation of ethanol intake and preference. The two-bottle choice procedure was used to examine the effects of the selective PDE2 inhibitor Bay 60-7550 on ethanol intake. The sucrose and quinine intake (taste preference) and locomotor activity (sedative effects) were also measured to exclude the false positive effects of Bay 60-7550.
Treatment with Bay 60-7550 (1 and 3 mg/kg, i.p.) decreased ethanol intake and preference, without changing total fluid intake. In addition, Bay 60-7550 at doses that reduced ethanol intake did not affect sucrose and quinine intake and preference, which excluded the potential influence of taste preference and sedative effects on ethanol drinking behavior. Moreover, Bay 60-7550 at 3 mg/kg did not alter locomotor activity or ethanol metabolism, further supporting the specific effect of Bay 60-7550 on ethanol drinking behavior.
The results suggest that PDE2 plays a role in the regulation of ethanol consumption and that PDE2 inhibitors may be a novel class of drugs for treatment of alcoholism.
KeywordsPDE2 Bay 60-7550 cAMP/cGMP Ethanol intake Two-bottle choice
This work was supported by research grants from NIH/NIAAA (HHSN275201700001C to H.-T. Zhang), National Nature Science Foundation of China (81773717 to H.-T. Zhang), and the Foundation of Overseas Distinguished Taishan Scholars of Shandong Province, China (to H.-T. Zhang). This work was also supported by The “13th Five-Year” Chinese Medicine Key Discipline in Zhejiang Province-Chinese Medicine Quality and functional evaluation (2017-XK-A43 to J. Shi).
- Blednov YA, Benavidez JM, Black M, Harris RA (2014) Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci 27(8):129. https://doi.org/10.3389/fnins.2014.00129.eCollection. Google Scholar
- Deng C, Wang D, Bugaj-Gaweda B, De Vivo M (2007) Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10). Curr Protoc Neurosci. Chapter 7:Unit 7.21. doi: https://doi.org/10.1002/0471142301.ns0721s38.
- Ding L, Zhang C, Masood A, Li J, Sun J, Nadeem A, Zhang HT, JM OD, Xu Y (2014) Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanisms. Behav Brain Res 268:150–158CrossRefPubMedPubMedCentralGoogle Scholar
- Driessen M, Schulte S, Luedecke C, Schaefer I, Sutmann F, Ohlmeier M, Kemper U, Koesters G, Chodzinski C, Schneider U, Broese T, Dette C, Havemann-Reinecke U, Group TR-S (2008) Trauma and PTSD in patients with alcohol, drug, or dual dependence: a multi-center study. Alcohol Clin Exp Res 32:481–488CrossRefPubMedGoogle Scholar
- Logrip ML, Zorrilla EP (2014) Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal. Front Integr Neurosci 8(30). https://doi.org/10.3389/fnint.2014.00030.eCollection2014.
- Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681–690CrossRefPubMedGoogle Scholar
- Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J (2003) mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467:566–580CrossRefPubMedGoogle Scholar
- Wang L, Xiaokaiti Y, Wang G, Xu X, Chen L, Huang X, Liu L, Pan J, Hu S, Chen Z, Xu Y (2017) Inhibition of PDE2 reverses beta am dependent yloid induced memory impairment through regulation of PKA/PKG- neuro-inflammatory and apoptotic pathways. Sci Rep 7:12044CrossRefPubMedPubMedCentralGoogle Scholar